Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest Exenatide Stories

2013-12-10 23:04:32

Reportbuyer.com just published a new market research report: PharmaPoint: Type 2 Diabetes - US Drug Forecast and Market Analysis to 2022. London (PRWEB) December 10, 2013 PharmaPoint: Type 2 Diabetes - US Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - US Drug Forecast and Market Analysis to 2022”. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a...

2013-12-10 12:32:53

JERUSALEM, December 10, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM:ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received allowance for a key patent from the Israeli Patent Office. The patent, entitled "Methods and Compositions for Oral Administration of Exenatide," covers oral exenatide compositions made using the company's proprietary technology....

2013-12-03 23:02:19

The Firm is investigating potential Byetta lawsuits on behalf of alleged victims of Byetta and pancreatic cancer, pancreatitis and thyroid cancer. New York., NY (PRWEB) December 03, 2013 Byetta lawsuits (http://www.byettalawsuit2013.com/ ), as well as product liability claims involving other incretin mimetic diabetes drugs, continue to move forward in a multidistrict litigation now underway in U.S. District Court, Southern District of California. According to an Order issued on November...

2013-12-02 16:23:23

- Former Merck executive who co-discovered Januvia, headed Merck's global diabetes & endocrinology franchise, and led Merck's research in metabolic disorders to help guide Intarcia - BOSTON, Dec. 2, 2013 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the appointment of Nancy Thornberry to its Board of Directors. Nancy's exceptional 34-year career at Merck demonstrates the power of her insight, innovation and ability to achieve competitively superior results in the...

2013-11-27 23:29:57

DrugRisk is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com New York, NY (PRWEB) November 27, 2013 The diabetes drug safety center at DrugRisk.com is alerting patients taking the medications Januvia or Janumet of new information on the site. Recent court records show the number of cases alleging drugs like Januvia caused pancreatic cancer have grown in November*. DrugRisk is a free resource provided to...

2013-11-27 23:29:32

Ruling affects plaintiffs’ claims and response from defendants over allegations that diabetes medications Byetta, Januvia, Janumet and Victoza cause pancreatic cancers. Resource4thePeople lawyers continue to offer free consultations for consumers seeking legal options for compensation. San Diego, CA (PRWEB) November 27, 2013 http://www.resource4thepeople.com/defectivedrugs/byetta.html Resource4thePeople announced today in its latest consumer update involving lawsuits* alleging that a...

2013-11-25 23:01:23

The Firm is now evaluating Byetta lawsuits that allege a link between the use of Byetta and pancreatic cancer, as well as pancreatitis and thyroid cancer. New York, New York (PRWEB) November 25, 2013 As Byetta lawsuit (http://www.byettalawsuit2013.com/ ) claims continue to mount in courts throughout the U.S., Bernstein Liebhard LLP notes the publication of a new study which supports an association between incretin mimetics like Byetta and pancreatic impairment, most notably pancreatitis....

2013-11-19 23:32:41

http://www.DrugNews.net is the web’s premier source for prescription device warnings, research, side effects and legal news. Visit the DrugNews Center today. Orlando, FL (PRWEB) November 19, 2013 The diabetes drug safety center at DrugNews.net is advising patients taking the medications Januvia or Janumet of updated information on the site. The latest court records show the number of patients alleging cancer from drugs like Januvia has grown in the past month*. DrugNews was created to...

2013-11-19 12:29:13

JERUSALEM, Nov. 19, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today that the European Patent Office has allowed the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins." Europe is one of the world's largest healthcare markets with an estimated $322 billion market value in 2012, accounting for over one quarter of the world pharmaceutical...

2013-11-16 23:02:02

The Firm is currently investigating Byetta lawsuits that allege an association between use of Byetta and pancreatic cancer, as well as pancreatitis and thyroid cancer. New York, New York (PRWEB) November 16, 2013 Dozens of Byetta lawsuits, (http://www.byettalawsuit2013.com/) as well as other product liability claims involving Januvia, Victoza and other diabetes drugs known as incretin mimetics, continue to move forward in a federal multidistrict litigation now underway in U.S. District...


Latest Exenatide Reference Libraries

36_67c6fec75293d7e1e91a0c52aa692cf7
2005-06-22 14:17:05

The Gila monster (Heloderma suspectum) is one of the two known species of venomous lizards. This lizard lives in the deserts of the southwestern USA and northwestern Mexico. It is a heavy, slow moving lizard and can measure up to 2 feet (60 cm) in length. Its skin has the appearance of beads in the colors black, pink, orange, and yellow, laid down in intricate patterns across the animal's body. Unlike a snake, the Gila monster envenomates its victim through grooves in the teeth of its...

More Articles (1 articles) »